Use of arf6 as a scaffold protein in the preparation of engineered extracellular vesicles

By using ARF6 as a scaffold protein, the problems of low loading efficiency and unstable expression of extracellular vesicles in existing technologies are solved, achieving efficient and stable loading of target proteins, which is suitable for drug delivery systems, especially for the delivery of therapeutic proteins and peptides.

CN122124273APending Publication Date: 2026-06-02SHENZHEN KEXING PHARM CO LTD +1
View PDF 0 Cites 0 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
SHENZHEN KEXING PHARM CO LTD
Filing Date
2026-05-07
Publication Date
2026-06-02

AI Technical Summary

Technical Problem

Existing scaffold proteins have low loading efficiency in extracellular vesicles and unstable expression, which affects their biological activity and therapeutic effects. Furthermore, some proteins need to be truncated or modified, increasing the difficulty of construction and potential impact on cell activity.

Method used

Using ARF6 as a scaffold protein, without the need for truncation or modification, it directly mediates the enrichment of the target protein in extracellular vesicles. By constructing a fusion protein expression vector of ARF6 and the target protein, the engineered extracellular vesicles are purified using differential ultracentrifugation and size exclusion chromatography.

Benefits of technology

It achieves efficient and stable loading of target proteins, reduces engineering difficulty, ensures biosafety, is suitable for large-scale production, and is applicable to drug delivery systems, especially for the delivery of therapeutic proteins and peptides.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN122124273A_ABST
    Figure CN122124273A_ABST
Patent Text Reader

Abstract

This invention provides the application of ARF6 as a scaffold protein in the preparation of engineered extracellular vesicles, belonging to the field of biomedical technology. The application of ARF6 (SEQ ID NO.1) as a scaffold protein in the preparation of engineered extracellular vesicles (EVs) provided by this invention. This invention uses natural full-length ARF6 as a scaffold protein to prepare engineered EVs, fully leveraging its comprehensive advantages of short gene sequence, high editing and synthesis efficiency, strong loading capacity, and good versatility. It effectively overcomes the technical bottlenecks of existing EV drug delivery systems, such as low loading efficiency and complex construction processes, successfully constructing a highly efficient, universal, and safe protein and peptide drug delivery platform. The technical solution of this invention showed good anti-inflammatory effects in both cellular inflammation models and sepsis mouse models, indicating that this invention has significant clinical application value and industrialization prospects in the fields of drug delivery and disease treatment.
Need to check novelty before this filing date? Find Prior Art